Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Seres Therapeutics, Inc.MCRB · Entity 7191 | See Remarks | August 15, 2026 | August 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Seres Therapeutics, Inc.
Report date August 15, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,117 |
Ending reported balance
After 2026-08-17 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-15 · Exercise / conversion · Acquired 245 · Balance 8,199 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Row 2 · 2026-08-17 · Sale · Disposed 82 · Balance 8,117 F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 265 |
Reported balance
After 2026-08-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-15 · Exercise / conversion · Disposed 133 · Balance 265 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 667 |
Reported balance
After 2026-08-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-08-15 · Exercise / conversion · Disposed 112 · Balance 667 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
F3: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
F4: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 17, 2026 Filed Aug 18, 2026 21:22 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 82 | $4.55 | $373.10 |
DisclosureSEC source: 0001193125-26-355712 · ownership.xml · nonDerivative · entry 2 DesRosier Thomas · CIK 0001435744 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,117 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:22 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 112 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-355712 · ownership.xml · derivative · entry 4 DesRosier Thomas · CIK 0001435744 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 667 Underlying: Common Stock · 112 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:22 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 133 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-355712 · ownership.xml · derivative · entry 3 DesRosier Thomas · CIK 0001435744 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 265 Underlying: Common Stock · 133 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:22 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 245 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-355712 · ownership.xml · nonDerivative · entry 1 DesRosier Thomas · CIK 0001435744 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,199 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| July 08, 2026 Filed Jul 10, 2026 20:15 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $9.13 | $0.00 |
DisclosureSEC source: 0001193125-26-300919 · ownership.xml · derivative · entry 1 DesRosier Thomas · CIK 0001435744 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2036-03-03 F1 · derivative.exercise_date: The option will vest as to 25% of the shares on March 2, 2027. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Read SEC document |
| May 18, 2026 Filed May 19, 2026 20:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 79 | $7.53 | $594.87 |
DisclosureSEC source: 0001193125-26-230728 · ownership.xml · nonDerivative · entry 2 DesRosier Thomas · CIK 0001435744 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,954 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 111 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-230728 · ownership.xml · derivative · entry 4 DesRosier Thomas · CIK 0001435744 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 779 Underlying: Common Stock · 111 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 133 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-230728 · ownership.xml · derivative · entry 3 DesRosier Thomas · CIK 0001435744 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 398 Underlying: Common Stock · 133 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 244 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-230728 · ownership.xml · nonDerivative · entry 1 DesRosier Thomas · CIK 0001435744 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,033 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 21:31 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (right to buy) · Derivative | 22,500 | $0.00 Strike: $9.13 | $0.00 |
DisclosureSEC source: 0001193125-26-096678 · ownership.xml · derivative · entry 1 DesRosier Thomas · CIK 0001435744 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2036-03-03 F1 · derivative.exercise_date: The option will vest as to 25% of the shares on March 2, 2027. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:30 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 111 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-057154 · ownership.xml · derivative · entry 4 DesRosier Thomas · CIK 0001435744 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 890 Underlying: Common Stock · 111 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:30 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 133 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-057154 · ownership.xml · derivative · entry 3 DesRosier Thomas · CIK 0001435744 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 531 Underlying: Common Stock · 133 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:30 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 78 | $8.47 | $660.66 |
DisclosureSEC source: 0001193125-26-057154 · ownership.xml · nonDerivative · entry 2 DesRosier Thomas · CIK 0001435744 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,789 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:30 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 244 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-057154 · ownership.xml · nonDerivative · entry 1 DesRosier Thomas · CIK 0001435744 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,867 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| November 15, 2025 Filed Nov 18, 2025 21:30 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 112 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-286240 · ownership.xml · derivative · entry 5 DesRosier Thomas · CIK 0001435744 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,001 Underlying: Common Stock · 112 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| November 15, 2025 Filed Nov 18, 2025 21:30 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 132 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-286240 · ownership.xml · derivative · entry 4 DesRosier Thomas · CIK 0001435744 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 664 Underlying: Common Stock · 132 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| November 15, 2025 Filed Nov 18, 2025 21:30 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 76 | $17.30 | $1,314.80 |
DisclosureSEC source: 0001193125-25-286240 · ownership.xml · nonDerivative · entry 3 DesRosier Thomas · CIK 0001435744 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,623 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. Read SEC document |
| November 15, 2025 Filed Nov 18, 2025 21:30 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 112 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-286240 · ownership.xml · nonDerivative · entry 2 DesRosier Thomas · CIK 0001435744 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,699 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| November 15, 2025 Filed Nov 18, 2025 21:30 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 132 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-286240 · ownership.xml · nonDerivative · entry 1 DesRosier Thomas · CIK 0001435744 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,587 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| August 18, 2025 Filed Aug 19, 2025 20:07 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 76 | $16.65 | $1,265.40 |
DisclosureSEC source: 0001193125-25-183436 · ownership.xml · nonDerivative · entry 3 DesRosier Thomas · CIK 0001435744 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,455 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 20:07 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 111 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-183436 · ownership.xml · derivative · entry 5 DesRosier Thomas · CIK 0001435744 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,113 Underlying: Common Stock · 111 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 20:07 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 133 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-183436 · ownership.xml · derivative · entry 4 DesRosier Thomas · CIK 0001435744 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 796 Underlying: Common Stock · 133 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 20:07 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 111 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-183436 · ownership.xml · nonDerivative · entry 2 DesRosier Thomas · CIK 0001435744 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,531 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 20:07 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 133 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-183436 · ownership.xml · nonDerivative · entry 1 DesRosier Thomas · CIK 0001435744 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,420 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| May 15, 2025 Filed May 19, 2025 20:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 111 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-074325 · ownership.xml · derivative · entry 5 DesRosier Thomas · CIK 0001435744 · Chief Legal Officer and EVP 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,224 Underlying: Common Stock · 111 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F5 · derivative.exercise_date: The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F5 · derivative.expiration_date: The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F2 · balance_after: Reflects a 1-for-20 reverse stock split effected on April 21, 2025. Read SEC document |
| May 15, 2025 Filed May 19, 2025 20:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 133 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-074325 · ownership.xml · derivative · entry 4 DesRosier Thomas · CIK 0001435744 · Chief Legal Officer and EVP 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 929 Underlying: Common Stock · 133 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F2 · balance_after: Reflects a 1-for-20 reverse stock split effected on April 21, 2025. Read SEC document |
| May 15, 2025 Filed May 19, 2025 20:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 79 | $7.28 | $575.12 |
DisclosureSEC source: 0000950170-25-074325 · ownership.xml · nonDerivative · entry 3 DesRosier Thomas · CIK 0001435744 · Chief Legal Officer and EVP 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,287 F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F2 · balance_after: Reflects a 1-for-20 reverse stock split effected on April 21, 2025. Read SEC document |
| May 15, 2025 Filed May 19, 2025 20:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 111 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-074325 · ownership.xml · nonDerivative · entry 2 DesRosier Thomas · CIK 0001435744 · Chief Legal Officer and EVP 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,366 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · balance_after: Reflects a 1-for-20 reverse stock split effected on April 21, 2025. Read SEC document |
| May 15, 2025 Filed May 19, 2025 20:05 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 133 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-074325 · ownership.xml · nonDerivative · entry 1 DesRosier Thomas · CIK 0001435744 · Chief Legal Officer and EVP 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,255 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · balance_after: Reflects a 1-for-20 reverse stock split effected on April 21, 2025. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 01:07 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 4,300 | $0.81 | $3,485.15 |
DisclosureSEC source: 0000950170-25-023573 · ownership.xml · nonDerivative · entry 3 DesRosier Thomas · CIK 0001435744 · Chief Legal Officer and EVP 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,456 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F3 · price: The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.81 to $0.8385, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 15, 2025 Filed Feb 20, 2025 01:07 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 8,907 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-023573 · ownership.xml · derivative · entry 5 DesRosier Thomas · CIK 0001435744 · Chief Legal Officer and EVP 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,718 Underlying: Common Stock · 8,907 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F5 · derivative.exercise_date: The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F5 · derivative.expiration_date: The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| February 15, 2025 Filed Feb 20, 2025 01:07 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 2,657 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-023573 · ownership.xml · derivative · entry 4 DesRosier Thomas · CIK 0001435744 · Chief Legal Officer and EVP 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,250 Underlying: Common Stock · 2,657 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| February 15, 2025 Filed Feb 20, 2025 01:07 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 8,907 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-023573 · ownership.xml · nonDerivative · entry 2 DesRosier Thomas · CIK 0001435744 · Chief Legal Officer and EVP 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 146,756 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 15, 2025 Filed Feb 20, 2025 01:07 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 2,657 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-023573 · ownership.xml · nonDerivative · entry 1 DesRosier Thomas · CIK 0001435744 · Chief Legal Officer and EVP 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 137,849 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 07, 2025 Filed Feb 11, 2025 21:15 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (Right to Buy) · Derivative | 650,000 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0000950170-25-017910 · ownership.xml · derivative · entry 1 DesRosier Thomas · CIK 0001435744 · Chief Legal Officer and EVP 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 650,000 Underlying: Common Stock · 650,000 shares Expires 2035-02-06 F1 · derivative.exercise_date: The option will vest as to 25% of the shares on February 7, 2026. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Read SEC document |
| November 18, 2024 Filed Nov 19, 2024 21:21 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 878 | $0.54 | $474.73 |
DisclosureSEC source: 0000950170-24-128631 · ownership.xml · nonDerivative · entry 2 DesRosier Thomas · CIK 0001435744 · Chief Legal Officer and EVP 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 135,192 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F3 · price: The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.5406 to $0.5442, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 21:21 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 2,656 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-128631 · ownership.xml · derivative · entry 3 DesRosier Thomas · CIK 0001435744 · Chief Legal Officer and EVP 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,907 Underlying: Common Stock · 2,656 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 21:21 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 2,656 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-128631 · ownership.xml · nonDerivative · entry 1 DesRosier Thomas · CIK 0001435744 · Chief Legal Officer and EVP 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 136,070 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| October 28, 2024 Filed Oct 29, 2024 22:26 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 4,259 | $0.69 | $2,939.14 |
DisclosureSEC source: 0000950170-24-118415 · ownership.xml · nonDerivative · entry 2 DesRosier Thomas · CIK 0001435744 · Chief Legal Officer and EVP 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 133,414 F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on May 4, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F4 · price: The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.69 to $ 0.6934, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 27, 2024 Filed Oct 29, 2024 22:26 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 13,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-118415 · ownership.xml · derivative · entry 3 DesRosier Thomas · CIK 0001435744 · Chief Legal Officer and EVP 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date. F1 · derivative.exercise_date: On February 3, 2023, the reporting person was granted an award of 27,001 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 13,501 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 13,500 RSUs vested and settled on October 27, 2024, the date that was eighteen months from the Initial Milestone Date. F2 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date. Read SEC document |
| October 27, 2024 Filed Oct 29, 2024 22:26 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 13,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-118415 · ownership.xml · nonDerivative · entry 1 DesRosier Thomas · CIK 0001435744 · Chief Legal Officer and EVP 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 137,673 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On February 3, 2023, the reporting person was granted an award of 27,001 restricted stock units ("RSUs"), which vest in the form of shares of the Issuer's common stock in two substantially equal installments upon the satisfaction of certain performance criteria. On April 27, 2023 (the "Initial Milestone Date"), the Issuer's Administrator determined that the performance criteria for the first installment were met, resulting in the vesting and settlement of the award as to 13,501 RSUs on October 27, 2023, the date that was six months from the Initial Milestone Date. The remaining 13,500 RSUs vested and settled on October 27, 2024, the date that was eighteen months from the Initial Milestone Date. F2 · price: Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs do not have an expiration date. Read SEC document |
| August 16, 2024 Filed Aug 19, 2024 21:48 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 873 | $0.84 | $733.32 |
DisclosureSEC source: 0000950170-24-098719 · ownership.xml · nonDerivative · entry 2 DesRosier Thomas · CIK 0001435744 · Chief Legal Officer and EVP 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,173 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F3 · price: The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.8414 to $0.8863, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 21:48 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 2,656 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-098719 · ownership.xml · derivative · entry 3 DesRosier Thomas · CIK 0001435744 · Chief Legal Officer and EVP 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,563 Underlying: Common Stock · 2,656 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 21:48 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 2,656 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-098719 · ownership.xml · nonDerivative · entry 1 DesRosier Thomas · CIK 0001435744 · Chief Legal Officer and EVP 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125,046 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| May 15, 2024 Filed May 18, 2024 00:14 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 2,656 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-062052 · ownership.xml · derivative · entry 3 DesRosier Thomas · CIK 0001435744 · Chief Legal Officer and EVP 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,219 Underlying: Common Stock · 2,656 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| May 15, 2024 Filed May 18, 2024 00:14 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 843 | $0.94 | $792.42 |
DisclosureSEC source: 0000950170-24-062052 · ownership.xml · nonDerivative · entry 2 DesRosier Thomas · CIK 0001435744 · Chief Legal Officer and EVP 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 122,390 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F3 · price: The price reported in column 4 is a weighted average of the sale prices. These shares were sold in multiple transactions at prices ranging from $0.94 to $0.943, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 15, 2024 Filed May 18, 2024 00:14 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 2,656 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-062052 · ownership.xml · nonDerivative · entry 1 DesRosier Thomas · CIK 0001435744 · Chief Legal Officer and EVP 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 123,233 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 16, 2024 Filed Feb 17, 2024 02:48 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 3,939 | $1.08 | $4,254.12 |
DisclosureSEC source: 0000950170-24-016712 · ownership.xml · nonDerivative · entry 2 DesRosier Thomas · CIK 0001435744 · Chief Legal Officer and EVP 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,577 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F3 · price: The price reported in column 4 is a weighted average of the price. These shares were sold in multiple transactions at prices ranging from $1.08 to $1.115, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 15, 2024 Filed Feb 17, 2024 02:48 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 10,625 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-016712 · ownership.xml · derivative · entry 6 DesRosier Thomas · CIK 0001435744 · Chief Legal Officer and EVP 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,875 Underlying: Common Stock · 10,625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F7 · derivative.exercise_date: The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F7 · derivative.expiration_date: The restricted stock units have vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. Read SEC document |
| February 15, 2024 Filed Feb 17, 2024 02:48 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 10,625 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-016712 · ownership.xml · nonDerivative · entry 1 DesRosier Thomas · CIK 0001435744 · Chief Legal Officer and EVP 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,516 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.